Colorado-Based GlobeImmune, Inc. Gives IPO A Second Shot, Aims For $35 Million

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Maybe the second time will be the charm for GlobeImmune, a Louisville, CO-based biotech that filed for an IPO on Monday after seeing its first effort to do so come up empty. The company, which initially filed for an IPO in 2012 but cancelled those plans last October after it couldn’t find buyers, is looking to raise $35 million through a new offering—less than half the roughly $75 million sum it attempted to raise the first time around, according to its prospectus. GlobeImmune was founded in 1995 and is developing potential cancer and infectious disease treatments that are designed to work by stimulating T cells to seek out and attack certain specific, infected cells.

Help employers find you! Check out all the jobs and post your resume.

Back to news